Breakthru Medicine

Phoenix, United States

Breakthru Medicine develops novel therapeutic modalities aimed at treating cancer by targeting hard-to-drug disease mechanisms.

$60.0M raised

Jan 2026

Series A

Biotechnology Oncology Pharmaceutical Therapeutics

Top Investors

Dave MoreheadFred EshelmanMark J. Gergen

Founder Contacts

19,000+ verified contacts

Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Breakthru Medicine

How much funding has Breakthru Medicine raised?

Breakthru Medicine has raised $60.0M in total funding. The most recent round was Series A. The last funding was announced in January 2026.

Who are Breakthru Medicine's investors?

Breakthru Medicine's investors include Dave Morehead, Fred Eshelman, Mark J. Gergen.

Where is Breakthru Medicine headquartered?

Breakthru Medicine is headquartered in Phoenix, United States.

What does Breakthru Medicine do?

Breakthru Medicine develops novel therapeutic modalities aimed at treating cancer by targeting hard-to-drug disease mechanisms.

What stage is Breakthru Medicine at?

Breakthru Medicine is at the Series A stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated January 29, 2026.

MLA

"Breakthru Medicine — Funding & Investors." VCBacked, January 29, 2026, https://www.vcbacked.co/company/breakthru-medicine. Accessed June 3, 2026.

APA

VCBacked. (2026). Breakthru Medicine — Funding & Investors. Retrieved June 3, 2026, from https://www.vcbacked.co/company/breakthru-medicine

Wikipedia (cite web)

{{cite web |title=Breakthru Medicine — Funding & Investors |url=https://www.vcbacked.co/company/breakthru-medicine |website=VCBacked |access-date=June 3, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated January 29, 2026.

Similar Companies in Biotechnology